The Latest
Guest Post: IP Rights are the Key to COVID-19 Vaccines
March 9, 2021Real-life outcomes have shown that IP opponents’ concerns that IP would hinder Covid-19 vaccine research and pricing are unfounded. Now critics blame IP for holding up the manufacture of the billions of doses required to meet global demand. In reality however, as the Geneva Network lays out in this week’s guest blog post, IP rights have enabled and accelerated the process of vaccine development and distribution.
